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RESEARCH ARTICLE
Xanthohumol inhibits PRRSV proliferation 
and alleviates oxidative stress induced by PRRSV 
via the Nrf2–HMOX1 axis
Xuewei Liu1, Zhongbao Song1, Juan Bai1, Hans Nauwynck2, Yongxiang Zhao1 and Ping Jiang1,3*
Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a prevalent and endemic swine pathogen that causes 
significant economic losses in the global swine industry. Commercial vaccines provide limited protection against 
this virus, and no highly effective therapeutic drugs are yet available. In this study, we first screened a library of 386 
natural products and found that xanthohumol (Xn), a prenylated flavonoid found in hops, displayed high anti-PRRSV 
activity by inhibiting PRRSV adsorption onto and internalization into cells. Transcriptome sequencing revealed that Xn 
treatment stimulates genes associated with the antioxidant response in the nuclear factor-erythroid 2-related factor 2 
(Nrf2) signalling pathway. Xn causes increased expression of Nrf2, HMOX1, GCLC, GCLM, and NQO1 in Marc-145 cells. 
The action of Xn against PRRSV proliferation depends on Nrf2 in Marc-145 cells and porcine alveolar macrophages 
(PAMs). This finding suggests that Xn significantly inhibits PRRSV proliferation and decreases viral-induced oxidative 
stress by activating the Nrf2–HMOX1 pathway. This information should be helpful for developing a novel prophylactic 
and therapeutic strategy against PRRSV infection.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Porcine reproductive and respiratory syndrome (PRRS) 
is one of the most economically detrimental swine dis-
eases worldwide. Infection is characterized by reproduc-
tive failure and preterm birth in sows as well as dyspnoea 
of piglets and fattening pigs [1, 2]. The aetiologic agent 
is PRRS virus, a positive-sense, single-stranded RNA 
virus belonging to the family Arteriviridae in the order 
Nidovirales. PRRSV is divided into two genotypes, the 
European genotype (type I) and the North American gen-
otype (type II), which share approximately 60% identity 
in amino acid sequences [3]. The mutation rate of PRRSV 
is 3.29 × 10−3 substitutions per nucleotide site per year in 
China alone [4, 5]. Commercially available vaccines can 
provide only incomplete protection. Modified live virus 
(MLV) vaccines protect against homologous strains [6], 
but they have the potential risk of reverting to a more 
virulent form or recombining with pandemic strains 
to form a novel genotype strain during serial passage in 
pigs [7]. These problems highlight the need for alterna-
tive approaches to control this disease. A combination of 
pharmacological intervention and vaccination is worthy 
of further inquiry.
The interaction between PRRSV and pigs has been 
well studied. Several host antiviral factors, such as the 
interferon-stimulated genes (ISGs) viperin [8], myxo-
virus resistance 2 (Mx2) [9], 2′,5′-oligoadenylate syn-
thetase 1 (OAS1) [10], interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3) [11], and CH25H [12, 
13], have been reported to have antiviral activity against 
PRRSV infection. Some microRNAs, small interfering 
RNAs (siRNAs) [14], and short-hairpin RNAs (shRNAs) 
[15] have also been shown to inhibit PRRSV replication. 
Meanwhile, some natural compounds and compositions 
have also been reported to have anti-PRRSV activity 
in  vitro, such as sodium tanshinone IIA sulfonate [16], 
proanthocyanidin A2 [17], Griffithsin [18], and (-)-epi-
gallocatechin-3-gallate [19]. However, the mechanism of 
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antiviral activity is not deeply understood. In this study, 
we screened a library of 386 natural products and found 
that xanthohumol, a prenylated flavonoid extracted from 
the hop plant Humulus lupulus L, significantly inhibited 
the early stages of PRRSV infection and inhibited virally 
induced oxidative stress by activating the Nrf2–HMOX1 
pathway in Marc-145 cells and PAMs, demonstrating 
excellent potential as a therapeutic agent.
Materials and methods
Cells, viruses, and reagents
Marc-145 cells (an African green embryonic kidney epi-
thelial cell line, ATCC) were cultured in Dulbecco’s mod-
ified Eagle’s medium (Invitrogen, USA) supplemented 
with 10% foetal bovine serum (FBS; GIBCO) at 37 °C in a 
humidified atmosphere containing 5%  CO2. Porcine alve-
olar macrophages (PAMs) were collected from lung lav-
ages of 6-week-old Yorkshire pigs (free of PRRSV, PCV2, 
PRV), as previously described, and cultured in RPMI-
1640 (GIBCO) containing 10% FBS at 37 °C. Three North 
American genotype 2 PRRSV strains were employed. 
The highly pathogenic PRRSV strain BB0907 (GenBank 
accession no. HQ315835.1), which is maintained in our 
laboratory, was used for all experiments and is repre-
sented by “PRRSV” in this article. The PRRSV strains S1 
(GenBank accession no. DQ459471.1) and FJ1402 (Gen-
Bank accession no. KX169191.1) were also used but are 
specifically mentioned by name (S1, a classical strain; 
FJ1402, a NADC30-like strain).
Xanthohumol, purity > 99%, was used for in  vitro 
experiments (Selleck Chemicals, Houston TX, USA). 
Protoporphyrin IX cobalt chloride (CoPP), an inducer 
of HMOX1 expression, was purchased from Sigma (St. 
Louis, MO, USA).
Screening of a natural product library
A library of 386 natural products was purchased from 
Selleck Chemicals (Houston, TX, USA). These com-
pounds were stored as 10 mM stock solutions in DMSO 
at 80 °C until use. The workflow for screening the library 
is diagrammed in Figures 1A and B. Marc-145 cells were 
seeded in 96-well plates at 2 × 104 cells per well. When 
approximately 60% confluent, the cells were treated 
with 10  µM compound or DMSO (1  µL) for 1 h and 
then infected with PRRSV (0.01 MOI) or mock infected 
for 1 h. Cells were then washed with PBS, and culture 
medium containing 10 µM compound was added back to 
each well. At 48 h post-infection (hpi), the percentage of 
inhibition was calculated by CPE and IFA. For each assay, 
there were two technical replicates, i.e., two compound-
infected groups, two DMSO-PRRSV infected groups, and 
two DMSO-mock infected groups.
During the primary screening, compounds were 
screened out if they resulted in any observable cytotox-
icity or demonstrated less than a 50% reduction of CPE 
compared with that of the DMSO control group. For the 
second round of screening, cell viability had to be 80% 
or greater, and the inhibition of PRRSV had to be 80% or 
greater (0.01 MOI and 0.1 MOI) via IFA. The 50% inhibi-
tory concentration  (IC50) and 50% cytotoxic concentra-
tion  (CC50) of each remaining candidate compound were 
determined, and those that displayed dose-dependent 
inhibition of PRRSV and had a selectivity index greater 
than 10 were considered for further study.
Cell viability assay
Concentrations of Xn were added to cultures of Marc-
145 cells and incubated for 48  h at 37  °C. Cell viability 
was tested using a Cell Counting Kit-8 (CCK-8) (Beyo-
time, Nanjing, China) following the manufacturer’s 
instructions. The 50% cytotoxic concentration  (CC50) was 
calculated using GraphPad Prism 7.0 software. DMSO 
was used as the negative control.
PRRSV infectivity inhibition assay
An indirect immunofluorescence assay (IFA) was used to 
examine the effect of Xn on PRRSV-infected Marc-145 
cells. Two-fold serially diluted compounds were added 
to the culture medium of Marc-145 cells (final concen-
trations were 1  µM to 20  µM). DMSO was used as the 
negative control. PRRSV (0.01 MOI) was then added 
onto the cells, and cultures were incubated for 48  h at 
37  °C. Cells were then fixed with 4% paraformaldehyde 
in PBS and permeabilized with 0.1% Triton X-100. After 
three washes with PBS, cells were incubated with an anti-
PRRSV N-protein mAb (made in our laboratory) [20] for 
1 h at 37 °C. Cells were washed three times with PBS and 
then incubated with Alexa Fluor 594-conjugated goat 
anti-mouse IgG (H–L) (1:200, Proteintech) for 1 h at 37 °C 
in the dark. Nuclei were stained with DAPI (Invitrogen, 
China) for 10  min at room temperature. Immunofluo-
rescence was observed using a Nikon A1 confocal micro-
scope (Nikon A1; Nikon, Japan). The level of fluorescence 
was determined using ImageJ software. GraphPad Prism 
5.0 software was used to estimate the 50% inhibition con-
centration  (IC50) of each compound. The selectivity index 
(SI) was determined by the ratio of  CC50 to  IC50.
Western blot assay
Cells were lysed on ice for 15 min in lysis buffer (Beyo-
time, China), then resolved by SDS-PAGE and trans-
ferred to a nitrocellulose membrane. The membrane 
was blocked with 5% low-fat milk for 2 h at room tem-
perature and then probed with antibodies: anti-PRRSV 
N-protein (1:1000), anti-β-actin (1:1000; Santa Cruz, 
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Figure 1 Screening protocol for PRRSV inhibitors. A Screening procedure time course. Marc-145 cells were treated with 10 µM compound for 
1 h and then infected with PRRSV (0.01 MOI) for 1 h. Cells were washed with PBS and then incubated in medium containing 10 µM compound for 
another 48 h. B Screening process flowchart. The criteria for passing the primary screen were that the compound had no apparent cytotoxicity 
and that it reduced CPE by at least 50% compared with that of the positive controls. The criteria for passing the secondary screen were that the 
compound had to leave cells at least 80% viable and had to inhibit PRRSV (0.01 MOI and 0.1 MOI) by more than 80%. Compounds that passed 
the tertiary screen inhibited PRRSV in a dose-dependent manner and had a selective index greater than ten. C Each dot represents the percent 
inhibition of PRRSV (0.01 MOI) achieved with each compound. The dots located above the dotted line indicate 80% or greater inhibition. D IFA of 
infected cells treated with one of the five designated compounds. PRRSV N-protein is coloured red, and brightfield-imaged cells show CPE. E  IC50 
and  CC50 curves of the 5 designated compounds. The structure of each compound is inset. F SIs of the 5 designated compounds. Selectivity index 
(SI) = CC50/IC50
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CA, USA), anti-HMOX1 (1:1000; Proteintech, USA), and 
anti-human Nrf2 (1:1000; Proteintech) for 2  h at room 
temperature. Membranes were incubated with HRP-
conjugated goat anti-mouse and anti-rabbit IgG (H–L) 
secondary antibodies (1:1000; Beyotime, China). Bound 
proteins were visualized with a Tanon 5200 chemilumi-
nescence imaging system (Tanon, China).
RNA extraction and quantitative real‑time PCR
Total RNA was extracted from cells using a Total RNA 
Kit I (Omega Bio-tek). RNA was then reverse tran-
scribed using a HiScript II 1st Strand cDNA Synthesis Kit 
(Vazyme, China) following the manufacturer’s instruc-
tions. Quantitative RT-PCR was performed using  AceQ® 
qPCR  SYBR® Green Master Mix (Vazyme, China). Data 
are presented as the fold change in gene expression nor-
malized to GAPDH and relative to the mock-infected 
control. Each reaction was performed in triplicate, and 
the data are calculated as the mean (M) ± SEM. Primer 
sequences for genes are shown in Table 1.
Virus titration
Marc-145 cells grown in 96-well plates were infected 
with ten-fold serial dilutions of PRRSV. After 1 h at 37 °C, 
the culture medium was replaced with fresh DMEM-2% 
FBS. Viral titres were determined using endpoint dilu-
tion analysis at 5 days post-inoculation (dpi). The Reed–
Muench method was used to calculate the 50% tissue 
culture infected dose  (TCID50).
Time‑of‑addition experiment
To evaluate which stage of the PRRSV life cycle is 
affected by Xn, a time-of-addition experiment was per-
formed as shown in the timeline schematic (Figure 3A). 
Marc-145 cells seeded into 24-well plates were either 
pre-treated, co-treated, or post-treated with Xn rela-
tive to PRRSV inoculation. The experiment began when 
the cells reached 60% confluence and was noted as −1 
h. At 0  h, culture supernatants of the pre-treated cells 
were replaced by DMEM-2% FBS, cells were then inoc-
ulated with PRRSV (0.01 MOI), the co-treated group 
was treated with 10  µM Xn and PRRSV, and the post-
treated group was inoculated with PRRSV. At +1 h, the 
culture supernatants in the co- and post-treated groups 
were replaced with DMEM/2% FBS, and the post-treated 
group was treated with 10  µM Xn. Incubation of all 
groups continued for 48 h.
Virucidal activity assay
A virucidal activity assay was performed to determine 
whether Xn interacts with PRRSV directly. Xn (10 µM) or 
DMSO was incubated with PRRSV (0.001, 0.01, and 0.1 
MOI) at 37  °C for 2  h. Marc-145 cells in six-well plates 
were pre-cooled at 4 °C for 1 h. The culture supernatants 
were replaced with a mixture of Xn (10  µM) or DMSO 
and PRRSV. After incubation at 4 °C for another 1 h, cells 
were overlaid with DMEM containing 1% low-melting-
point agarose (Sigma-Aldrich) and 2% FBS and incubated 
for 72 h at 37 °C. The cells were overlaid with 1% crystal 
violet in methanol and incubated for an additional 2 h at 
37 °C. Plaque-forming units were counted.
Virus adsorption assay
Marc-145 cells cultured in 24-well plates were pre-chilled 
at 4 °C for 1 h. Culture supernatants were then replaced 
by a 4  °C mixture of Xn (5, 10, and 15  µM) or DMSO 
and PRRSV (1 MOI) and incubated at 4  °C for another 
1  h. Cells were washed with ice-cold PBS, and then the 
mRNA levels of PRRSV ORF7 in cells were measured 
using qRT-PCR.
Virus internalization assay
Marc-145 cells were plated, grown to approximately 
70% confluence, pre-treated with cycloheximide (CHX) 
(10 μg/mL) for 12 h, washed and incubated with PRRSV 
(1 MOI) for 1 h at 4  °C to allow virus attachment. Cells 
were washed 3 times with ice-cold PBS to remove 
unbound virus. Then, the culture medium was replaced 
Table 1 Primer sequences of probes used for qPCR 
analysis 
p means pig and m means monkey
Primer Sequence (5′ → 3′)
mGAPDH-Fwd 5′ CCT TCC GTG TCC CTA CTG CCAA 3′
mGAPDH-Rev 5′ GAC GCC TGC TTC ACC ACC TTCT 3′
mHMOX-1-Fwd 5′ CTT CAA GCT GGT GAT GGC 3′
mHMOX-1-Rev 5′ TGG AGC CGC TTC ACA TAG 3′
mNrf2-Fwd 5′ ATT CAA TGA TTC TGA CTC TG 3′
mNrf2-Rev 5′ CGT ATC CCC AGA AGA ATG TA 3′
mNQO1-Fwd 5′ CAT GTA CTC TCT GCA AGG GA 3′
mNQO1-Rev 5′ TCC CAA ATA TTC TCC AGG CG 3′
mTXNRD1-Fwd 5′ TGT TGT GGG CTT TCA CGT AC 3′
mTXNRD1-Rev 5′ ATG TTG TGA ATA CCT CTG CA 3′
mTNXIP-Fwd 5′ CGA CCC TGA AAA GGT GTA C 3′
mTNXIP-Rev 5′ CGA ACT TGT ACT CAT ATT TG 3′
mGCLM-Fwd 5′ TCA GTG GGC ACA GGT AAA A 3′
mGCLM-Rev 5′ TTG TTT AGC AAA TGC AGT CA 3′
mGCLC-Fwd 5′ ACA TGC GAA AAC GGC GGA A 3′
mGCLC-Rev 5′ CGA GGG TGC TTG TTT ATT GC 3′
pHMOX-1-Fwd 5′ GGC TGA GAA TGC CGA GTT 3′
pHMOX-1-Rev 5′ ATG TAG CGG GTG TAG GCG 3′
PRRSV-ORF7-Fwd 5′ AAA CCA GTC CAG AGG CAA G 3′
PRRSV-ORF7-Rev 5′ TCA GTC GCA AGA GGG AAA T 3′
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with fresh DMEM containing 10  µM Xn or DMSO, 
and the cells were incubated for 2 h at 37 °C. Cells were 
washed with citrate buffer (pH 3) to remove non-inter-
nalized virus. The levels of PRRSV ORF7 mRNA were 
detected by qRT-PCR, and the virions in cells were 
detected and visualized using IFA confocal laser-scan-
ning microscopy.
Virus replication assay
Marc-145 cells were incubated with PRRSV (1 MOI) at 
37  °C. At 6 hpi, cells were washed 3 times with PBS to 
remove free virus, the culture medium was replaced with 
fresh DMEM-2% FBS containing Xn (10 µM) or DMSO, 
and the cultures were incubated at 37 °C. At 7, 8, 9, and 
10 hpi, PRRSV genome levels in cells were measured 
using qRT-PCR.
Virus release assay
Marc-145 cells were infected with PRRSV (0.1 MOI) for 1 h 
at 37 °C, and the culture medium was then replaced with 
fresh DMEM-2% FBS. At 24 hpi, the cells were washed 3 
times with PBS, the culture medium was replaced with 
fresh DMEM-2% FBS containing Xn (10  µM) or DMSO, 
and the cultures were incubated at 37  °C for 10, 30, and 
60  min, at which point the supernatants were harvested. 
Released virus was quantified by plaque assay.
RNA isolation, sequencing, and functional analysis
Marc-145 cells exposed to 10 μM Xn or DMSO for 4, 
8, and 12  h were collected for transcriptomic analy-
sis; for each time point, there were two biological repli-
cates. RNA isolation and sequencing were performed by 
Novogene Bioinformatics Technology Co., Ltd. (Beijing, 
China). Sequencing libraries were generated using an 
 NEBNext® UltraTM RNA Library Prep Kit for  Illumina® 
(NEB, USA) following the manufacturer’s recommenda-
tions. Index codes were added to attribute sequences to 
each sample. Briefly, total RNA was isolated using TRI-
zol reagent (Invitrogen, NJ, USA), and genomic DNA 
was then removed using DNase I (Invitrogen). mRNA 
was purified from total RNA using poly-T oligo-attached 
magnetic beads. First strand cDNA was synthesized 
using random hexamer primers. Second strand cDNA 
synthesis was subsequently performed using DNA poly-
merase I and RNase H. The double-stranded cDNAs 
were purified using AMPure XP beads, then used for 
end reparation and “A” base addition, and finally ligated 
with sequencing adapters. The adaptor-ligated frag-
ments were size selected using AMPure XP beads. After 
quantification using a Qubit 2.0 fluorometer (Life Tech-
nologies), cDNAs were used for PCR amplification and 
sequenced as 2 × 120  bp paired-end reads on an Illu-
mina HiSeq™  2000 sequencer (Illumina, San Diego, 
CA, USA). FeatureCounts v1.5.0-p3 was used to count 
the read numbers mapped to each gene, and then the 
FPKM (number of Fragments Per Kilobase of transcript 
sequence per Millions base pairs sequenced) of each 
gene was calculated based on the length of the gene. Dif-
ferential expression analysis of two conditions/groups 
(two biological replicates per condition) was performed 
using the DESeq2 R package. The resulting P-values 
were adjusted using Benjamini and Hochberg’s approach 
for controlling the false discovery rate. Genes with an 
adjusted P value < 0.05 found by DESeq2 were assigned 
as differentially expressed. Finally, GO and KEGG anal-
yses were performed to understand the effect of Xn on 
cell biological processes, molecular function, and cellular 
components. All raw sequence reads data were deposited 
in the NCBI Sequence Read Archive (SRA) with acces-
sion number PRJNA516508.
Plasmid construction
Total RNA was extracted from PAMs using a Total RNA 
Kit I (Omega Bio-tek, Norcross, GA, USA), and cDNA 
synthesis was performed with SuperScript III Reverse 
Transcriptase (Invitrogen). HMOX1 was generated by 
PCR amplification of cDNA from PAMs with the oligo-
nucleotide pair SacI HMOX1 5′-ACG AGC TCA TGG 
AGC GTC TGC AAC CCG ACA-3′ and NheI HMOX1 
5′-CGG CTA GCT CAA GCA ACG TCC GGA ACG 
TCG TAC GGG TAC ATG GCA TAA AGC-3′. The 
sequence of the amplification product was compared 
to that in the NCBI database for verification (GenBank 
accession no. NM_001004027.1), restriction digested, 
and cloned into the pCAGGS vector with an HA tag at its 
3′ end to produce pCAGGS-HMOX1.
Plasmid transfection and virus challenge
To determine the effects of HMOX1 on PRRSV replica-
tion, Marc-145 cells plated in 24-well plates were trans-
fected with 0, 0.4, 0.6 or 1.0  μg of pCAGGS-HMOX1 
using Lipofectamine 3000 (Invitrogen) according to the 
manufacturer’s recommendations. Twenty-four hours 
after transfection, the cells were infected with PRRSV 
(0.01 MOI) and then harvested for Western blotting at 48 
hpi.
Small interfering RNA assays
A total of 2 × 106 Marc-145 cells were transfected into 
24-well plates with 50  pmol of siNC (negative control) 
and siNrf2 (GenePharma, Shanghai, China) using 5 µL 
of Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, 
USA). After 24  h, the cells were treated with Xn and 
infected with PRRSV (0.01 MOI) for 36 h. Cells were har-
vested for Western blotting and qRT-PCR. The sequences 
of siRNAs targeting Nrf2 were: (a) 5′-AGA CAA ACA 
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TTC AAG CCG-3′; (b) 5′-AGA ATA AAG TGG CTG 
CTC-3′.
Reactive oxygen species (ROS) levels
Cellular levels of reactive oxygen species were deter-
mined using a dichlorofluorescein (DCF) ROS assay kit 
according to the manufacturer’s instructions (Beyotime 
Biotechnology, China). Marc-145 and PAM cells were 
infected with PRRSV (0.1 MOI) for 12 h and then treated 
with 5 µM Xn or DMSO for another 12 h. 10 mM DCF-
DA was added to the cells for 30 min at 37 °C. The Marc-
145 cells were washed and imaged using an inverted 
fluorescence microscope (Nikon). The PAMs were col-
lected by centrifugation, washed, and suspended in cold 
PBS; fluorescent intensity was analysed on a FACSCali-
bur (BD Biosciences, San Jose, CA, USA), and the data 
were analysed using FlowJo version 7.6.1. Cells treated 
with 12 µM  H2O2 for 3 h, washed, and then treated with 
DMSO or 5  µM Xn for another 12  h served as positive 
controls.
MDA, GSH and SOD levels
Levels of superoxide dismutase (SOD), glutathione per-
oxidase (GSH), and malondialdehyde (MDA) in cells 
were determined using a Superoxide Dismutase (SOD) 
assay kit, a Glutathione Peroxidase (GSH-PX) assay kit, 
and a Microscale Malondialdehyde (MDA) assay kit, 
respectively, following the manufacturers’ instructions 
(Jiancheng Bioengineering Institute, Nanjing, China). 
The levels were normalized to the protein concentration 
determined by a bicinchoninic acid (BCA) protein assay 
kit (Beyotime).
Statistical analyses
All statistical analyses were performed using GraphPad 
Prism (version 7.0, GraphPad Software, San Diego, CA, 
USA), and the data are expressed as the mean ± standard 
error of the mean. The significance of differences among 
groups was determined by one-way or two-way analysis 
of variance (ANOVA). Differences with p-values < 0.05 
were considered significant and are designated with * in 
the figures.
Results
Library screening
Marc-145 cells were treated with 10 µM natural product 
and infected with PRRSV as detailed in the timeline (Fig-
ure 1A). The results revealed that 24 (6.21%) compounds 
showed no apparent cytotoxicity and reduced CPE by 
50% compared to that with DMSO alone. These com-
pounds were subjected to a second round of screening 
(Figure 1B). Five of these compounds produced minimal 
cytotoxicity and inhibited PRRSV infection (0.01 MOI 
and 0.1 MOI) by more than 80%, as determined by IFA 
(Figures 1C and D). Of these 5 compounds, only xantho-
humol (Xn), curcumin, and chloroxin inhibited PRRSV in 
a dose-dependent manner and had a selectivity index (SI) 
greater than 10 (Figures 1E and F).
To determine the dose range of Xn anti-PRRSV activ-
ity, Marc-145 cells were treated with 5, 10, and 15  µM 
Xn for 1  h and then infected with PRRSV (0.01 MOI). 
 TCID50 and qRT-PCR assays performed at 24, 36, and 
48 hpi showed that virus titres and ORF7 mRNA levels 
decreased in a dose-dependent manner at each post-
infection time point (Figures 2A and B). At 48 hpi, CPE 
and IFA revealed that the number of infected cells in the 
Xn-treated groups was obviously less than that in the 
negative control (Figure 2C). Western blot analysis dem-
onstrated that Xn was as effective at reducing replication 
of the C-PRRSV S1 strain as it was at reducing replica-
tion of the BB0907 strain and was somewhat effective at 
reducing replication of the NADC30-like FJ1402 strain 
(Figure 2D).
Xanthohumol inhibits PRRSV infection
To begin to determine the mechanism of Xn inhibition 
of PRRSV, Marc-145 cells were treated with Xn before, 
during, and after PRRSV infection (Figure 3A). At 48 hpi, 
cells were observed for CPE, stained for IFA, and har-
vested for Western blotting. PRRSV inhibition was great-
est in cells treated with Xn for 1 h before infection and 
was significantly suppressed in cells treated with Xn dur-
ing infection. In cells treated with Xn for 24 h after infec-
tion, PRRSV was still suppressed but not to the extent 
seen in the pre- and co-treated cells (Figures 3B and C). 
To determine if Xn affected PRRSV directly, 10  µM Xn 
was mixed with virus, incubated for 2 h at 37 °C and then 
added onto Marc-145 cells. As shown in Figure  3D, the 
number of viral plaques in Xn + PRRSV cells was not 
obviously different from that in the DMSO + PRRSV 
control cells, indicating that Xn does not have a direct 
virucidal effect on PRRSV. Together, these data indicated 
that Xn inhibits PRRSV early in the infection process.
To determine what stage of the PRRSV life cycle is 
specifically affected by Xn, Marc-145 cells were chilled 
at 4 °C for 1 h, and the culture supernatants were then 
replaced with a 4  °C mixture of Xn or DMSO and 
PRRSV (1 MOI). After incubation at 4  °C for another 
1 h, the cells were washed and harvested for qRT-PCR 
of PRRSV ORF7 mRNA. The results showed that treat-
ment with Xn resulted in reduced viral RNA detec-
tion in a dose-dependent manner, indicating that Xn 
affects PRRSV at the adsorption stage (Figure  4A). In 
a companion experiment, cells (pre-treated with 10 μg/
mL CHX for 12  h) were incubated with PRRSV for 
1 h at 4 °C (to allow virus to attach), washed, and then 
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Figure 2 Identification of anti‑PRRSV activity of Xn in Marc‑145 cells. Marc-145 cells were pre-treated with the indicated concentrations of 
Xn (A–C) or 10 µM Xn (D) for 1 h and then infected with PRRSV (0.01 MOI) for 1 h at 37 °C. Cells were washed with PBS and then incubated in fresh 
medium containing Xn for 48 h (C) or the indicated times (A, B). DMSO served as the treatment control. A Culture supernatants were collected at 
the indicated time points for viral titration. The results are expressed as a 50% tissue culture infective dose  (TCID50). Titres from three independent 
experiments are shown as the means ± SEMs (error bars). B Relative PRRSV ORF7 mRNA levels determined by qRT-PCR and expressed relative to 
ORF7 mRNA levels in mock cells. GAPDH was the internal loading control. C At 48 hpi, light microscopy and IFA images of Marc-145 PRRSV-infected 
and Xn-treated cells. Viral N-protein is red, and nuclei are blue. D At 48 hpi, Western blot of N-protein in cells infected with different PRRSV 
genotypes and treated with 10 µM Xn or DMSO. All assays were performed in triplicate, with three technical repeats for each sample. Bars represent 
means ± SEMs from three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05
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incubated in fresh DMEM-2% FBS containing 10  µM 
Xn for 2 h at 37  °C. The cells were probed for PRRSV 
N-protein and observed by confocal laser-scanning 
microscopy. The results showed that Xn inhibits PRRSV 
entry into cells even after the virus has attached to the 
cells (Figure 4B). In cells incubated with PRRSV for 6 h 
at 37  °C and then treated with Xn in fresh DMEM-2% 
FBS at 37 °C for an additional 1, 2, 3, and 4 h, qRT-PCR 
results showed that viral mRNA levels in the Xn-treated 
cells were not significantly different from those in the 
DMSO-treated control cells (Figure 4C). To explore the 
role of Xn in PRRSV release, Marc-145 cells were incu-
bated with PRRSV for 24 h. The cells were washed and 
then incubated with fresh DMEM containing Xn for 
10, 30, and 60 min. The virus titres in the supernatants 
from the Xn-treated cells were not significantly differ-
ent than those in the supernatants from the DMSO-
treated control cells (Figure 4D). Taken together, these 
results indicate that Xn inhibits PRRSV at the stages of 
adsorption and internalization.
Transcriptional response of Marc‑145 cells to xanthohumol 
treatment
The effect of xanthohumol on the activation of the Nrf2 
pathway in human hepatocellular carcinoma (HCC) 
HepG2 cells, immortalized human liver THLE-2 cells 
and mouse lung tissues [21, 22] has been reported. To 
investigate the mechanism underlying the anti-PRRSV 
effect of Xn, we used high-throughput RNA sequenc-
ing to examine gene expression in Marc-145 cells that 
had been treated with 10  µM Xn or DMSO for 4, 8, 
and 12 h. Figure 6A shows the numbers of differentially 
expressed genes (DEGs) that were identified at each time 
point, using the criteria of p < 0.05. We classified a gene 
as upregulated if its transcript was more abundant in 
cells treated with Xn than in cells treated with DMSO. 
Figure 3 Xanthohumol inhibits PRRSV early in infection in Marc‑145 cells. A Time-of-addition schematic. Marc-145 cells were infected 
with PRRSV (0.01 MOI) for 1 h (0 to 1 h), and cells were treated with 10 µM Xn at different times of infection, designated pre-treatment (pre), 
co-treatment (co), or post-treatment (post). B The effect of Xn was determined by CPE and IFA. C The effect of different concentrations of Xn was 
detected by Western blotting. D Xn (10 µM) or DMSO was incubated with PRRSV (0.001, 0.01, and 0.1 MOI) for 2 h at 37 °C and then inoculated into 
Marc-145 cells. After incubation for 48 h at 37 °C, the viral titres were detected by  TCID50 assays. The results are representative of three independent 
experiments performed in triplicate
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Figure 4 Xn inhibits PRRSV adsorption and internalization in Marc‑145 cells. A Adsorption assay. Cells were incubated with a mixture of Xn or 
DMSO and PRRSV for 1 h at 4 °C and then harvested for qRT-PCR. B Internalization assay. Cells were treated with CHX (10 μg/mL) for 12 h first, then 
incubated with PRRSV (1 MOI) for 1 h at 4 °C, washed, and finally incubated with 10 µM Xn or DMSO for another 1 h at 37 °C. The levels of PRRSV 
ORF7 mRNA were detected by qRT-PCR, and the visible virions in cells were detected using IFA confocal laser-scanning microscopy. Scale bar 10 µm. 
C Cells were infected with PRRSV (1 MOI) for 6 h, and culture medium was replaced with 2% DMEM containing Xn (10 µM) or DMSO. At 7, 8, 9, and 
10 hpi, the PRRSV ORF7 levels were measured using qRT-PCR. D Cells were infected with PRRSV (0.1 MOI) for 18 h, then washed and incubated 
with fresh DMEM containing 10 µM Xn or DMSO. Supernatants were harvested, and released virus was titred by plaque assay. qRT-PCR results 
are presented relative to the reference control (mock infected cells). GAPDH was used as the internal loading control. All assays were repeated at 
least three times, with each experiment performed in triplicate. Bars represent the means ± SEMs from three independent experiments. **P < 0.01; 
*P < 0.05 compared with the DMSO-treated group
Page 10 of 21Liu et al. Vet Res           (2019) 50:61 
The number of DEGs increased with treatment time, and 
after 12 h, 2493 genes were upregulated, and 3065 down-
regulated. In total, 462 DEGs appeared at all three sam-
pled times (Figures 5B and C). GO analysis of the DEGs 
showed that the most enriched molecular functions were 
oxidoreductase activity and oxidation–reduction pro-
cesses, as marked by asterisks (Figure  5D). GO analysis 
of the top 100 DEGs according to log2 fold change at 8 h 
suggested that oxidoreductase activity and the oxidore-
ductase complex were activated at this time point (Addi-
tional file  1). We therefore investigated the networks 
associated with oxidoreductase and the antioxidant 
response. Further analysis identified a large set of genes 
associated with the antioxidant response, including Nrf2, 
HMOX1, GCLC, GCLM, and NQO1 (Figure 6A). These 
genes, which are all part of the Nrf2 signalling pathway, 
are transcriptionally activated through mainly binding of 
Nrf2 to antioxidant response elements (AREs) at their 5′ 
promoters [23]. 
To confirm the results of the RNA-seq analysis, a qRT-
PCR assay was conducted to measure the expression 
of Nrf2, HMOX1, GCLC, GCLM, NQO1, TXNIP, and 
TXNRD1 in Xn-treated cells. The results (Figures  6B–
H) showed that Xn treatment increased the expression 
of all 7 genes, consistent with the RNA-seq data. Taken 
together, these data indicate that Xn may protect against 
PRRSV infection by activating the host antioxidant 
response via stimulation of the Nrf2 signalling pathway.
Xanthohumol upregulates the Nrf2 antioxidative pathway, 
inhibiting PRRSV proliferation
HMOX1 (haem oxygenase 1) was highly upregulated 
at all three points in the RNA-seq analysis; it is a rate-
limiting enzyme in haem degradation, has cytoprotective 
effects against oxidative stress, and plays an important 
role in the resolution of inflammation [24]. To examine 
the role of Xn-induced HMOX1 expression in PRRSV 
suppression, Marc-145 cells were treated with 10  µM 
Xn for different times over 24  h, followed by qRT-PCR 
for HMOX1 mRNA. As shown in Figure  7A, HMOX1 
was induced by Xn in cells as a function of time until 
late in the experiment when induction levels fell sharply, 
indicating that Xn provides a continuous stimulus on 
HMOX1. We therefore investigated the role that HMOX1 
plays in the protective effect of Xn against PRRSV in 
Marc-145 and PAM cells. Marc-145 cells, when 70% con-
fluent, were transfected with different doses of pCAGGS-
HMOX1 and pCAGGS and then infected with PRRSV 
(MOI 0.01). At 48 hpi, the levels of viral N-protein and 
HMOX1 in the cell lysates were examined by Western 
blotting. The levels of viral ORF7 mRNA and titres were 
detected by qRT-PCR and  TCID50 assays. As expected, 
overexpression of HMOX1 in Marc-145 cells significantly 
inhibited PRRSV replication in a dose-dependent man-
ner (Figures  7B  and D). These results indicated that Xn 
inhibition of PRRSV is related to HMOX1.
HMOX1 transcription is modulated by an intertwined 
circuit in which nuclear factor E2-related factor 2 (Nrf2) 
plays an essential role [25]. To examine the role of Nrf2 
in the action of Xn against PRRSV infection, Marc-145 
cells were infected with PRRSV (0.1 MOI) for 1  h at 
37  °C and then cultured in medium containing 10  µM 
Xn or DMSO for 24  h. Total RNA was extracted from 
virus-infected cell lysates, and PRRSV ORF7 mRNA lev-
els and the levels of a set of Nrf2-regulated antioxidant 
genes were quantified by qRT-PCR. As shown in Fig-
ure 7E, the expression of these Nrf2-regulated genes was 
downregulated slightly by PRRSV infection but signifi-
cantly induced by Xn treatment. Infected cells treated 
with Xn had elevated mRNA expression of Nrf2 and 
its target genes, as well as decreased virus replication. 
Because we did not have a suitable Nrf2 antibody for 
detecting endogenous Nrf2 protein in Marc-145 cells, we 
used HMOX1 as an indicator of Nrf2 levels. As shown 
in Figure  7F, along with the decrease in N-protein, in 
PRRSV-infected cells treated with Xn, there was an 
accompanying increase in HMOX1. Xn treatment signif-
icantly inhibited PRRSV replication. In addition, Marc-
145 cells were transfected with siRNAs against Nrf2 or 
with a nonspecific siRNA control (NC). After incubation 
for 24 h, cells were infected with PRRSV (0.01 MOI). At 
36 hpi, cells were harvested for qRT-PCR and Western 
blotting. The results showed that the siRNAs siNrf2-
a and siNrf2-b efficiently knocked down Nrf2 mRNA 
and protein levels (Figures 7G and H) and resulted in a 
significant increase in PRRSV replication. These results 
indicate that Nrf2 is a crucial protein involved in the 
host defence mechanism against PRRSV.
Finally, to identify the role of Nrf2 in the anti-PRRSV 
effect of Xn, Marc-145 cells were transfected with siNrf2-
a or siNC. After 24 h, the cells were treated with 10 µM 
Xn for 1 h and then infected with PRRSV (0.01 MOI). At 
36 hpi, cells were harvested for qRT-PCR and Western 
blotting. As expected, Xn significantly decreased PRRSV 
ORF7 mRNA and N-protein levels in cells transfected 
with siNC. However, in cells transfected with siNrf2, 
Xn had no inhibitory effect on PRRSV infection (Fig-
ures 7I and J). These results suggest that Nrf2 could be an 
effective target against PRRSV and that the anti-PRRSV 
action of Xn depends on its activation of Nrf2 and the 
Nrf2-regulated antioxidant pathway.
Xn alleviates PRRSV‑stimulated oxidative stress
In Marc-145 cells, PRRSV infection induces oxidative 
stress in cells by generating reactive oxygen species 
(ROS), which play a key role in PRRSV pathogenesis 
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Figure 5 Transcriptional response of Marc‑145 cells to xanthohumol treatment. RNA profiling by RNA sequencing of Marc-145 cells treated 
with 10 µM Xn or DMSO for 4, 8, and 12 h. A Waterfall plot of the up- and downregulated genes at each time point (DEGs selected based on 
padj < 0.05). B Unsupervised hierarchical cluster analysis of DEGs. DEG expression levels are represented as FPKM-normalized  log2-transformed 
counts. Blue indicates low relative expression, and red indicates high relative expression. C Venn diagram of the unique and shared genes of each 
group. The cluster number for each component is listed. D Significantly enriched KEGG terms of the 462 shared genes
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[26]. Because of our transcriptome data regarding Xn-
induced oxidoreductase activity and the Nrf2-regulated 
antioxidant genes and because Nrf2 plays a crucial role 
in oxidative stress [27], we explored further whether 
the inhibitory activity of Xn against PRRSV infection 
is related to its antioxidant activity. Marc-145 cells pre-
treated with 12 µM  H2O2 for 3 h and then incubated with 
Xn produced less ROS than untreated cells. IFA results 
showed that PRRSV infection resulted in increased 
ROS, and Xn treatment reduced ROS in infected and 
uninfected cells (Figure  8A). MDA, a product of lipid 
peroxidation and a biomarker for estimating oxidative 
stress, was also dramatically reduced by Xn treatment 
(Figure 8B). Furthermore, the reduction in SOD and glu-
tathione peroxidase (GSH) as a result of PRRSV infec-
tion was alleviated by Xn (Figures 8C and D). These data 
indicate that Xn restores the oxidation balance in Marc-
145 cells.
Figure 6 Xanthohumol treatment upregulates the Nrf2 antioxidative pathway. A Heat map of expressed Nrf2 antioxidant genes modulated 
by 10 µM Xn or DMSO treatment in Marc-145 cells. Red and blue correspond to relative up- and downregulation, respectively. B–H qRT-PCR 
quantification of the expression levels of Nrf2-regulated genes at four time points after 10 µM Xn treatment. The qRT-PCR was repeated at least 
three times, with each experiment performed in triplicate. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 vs DMSO-treated cells for each time point
(See figure on next page.)
Figure 7 Xanthohumol upregulates Nrf2–HMOX1 to inhibit PRRSV proliferation. A Marc-145 cells were treated with 10 µM Xn for different 
times over 24 h, followed by qRT-PCR for HMOX1 mRNA. ***P < 0.001; **P < 0.01; *P < 0.05 vs DMSO-treated cells. B–D PRRSV replication in Marc-145 
cells transfected with the indicated doses of pCAGGS-HMOX1 for 24 h and then infected with PRRSV (0.01 MOI) for 48 h was evaluated by Western 
blotting,  TCID50 and qPCR. E Marc-145 cells were treated with Xn or DMSO for 1 h, then infected with PRRSV (0.1 MOI) for 1 h at 37 °C and finally 
cultured in medium containing 10 µM Xn or DMSO. Total RNA was extracted from lysates of cells at 24 hpi, and the mRNA levels of PRRSV ORF7 and 
a set of Nrf2-regulated antioxidant genes were detected by qRT-PCR. ###P < 0.001; ##P < 0.01; #P < 0.05 vs DMSO-treated cells. ***P < 0.001; **P < 0.01; 
*P < 0.05 vs DMSO + PRRSV cells. F Cells were lysed and samples were prepared for Western blotting. G qRT-PCR and H Western blot analysis 
were performed on Marc-145 cells transfected with 50 pmol of siNC or Nrf2 siRNAs (siNrf2-a and siNrf2-b) using 5 µL of Lipofectamine RNAiMAX 
transfection reagent for 24 h. Cells were then infected with PRRSV (0.01 MOI), and after 36 h, cells were harvested for assays. I qRT-PCR and J Western 
blot analysis were performed on Marc-145 cells transfected with siNrf2-a and siNC. After 24 h, cells were treated with 10 µM Xn or DMSO for 1 h and 
then infected with PRRSV (0.01 MOI). After 36 h, cells were harvested for assays. All results are means ± standard deviations from three independent 
experiments performed in triplicate. ***P < 0.001; **P < 0.01; *P < 0.05 compared with the control group
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Xanthohumol upregulates the Nrf2–HMOX1 antioxidative 
axis to inhibit PRRSV proliferation in PAMs
Given that PAMs are natural target cells in pigs, we iden-
tified the role of Xn in PRRSV-infected PAMs. First, 
PAMs were treated with DMSO or 5, 10, and 15  µM Xn 
for 1 h at 37 °C and then infected with PRRSV (MOI 0.1) 
for 1 h. Cells were washed and incubated in fresh culture 
medium containing 5, 10, and 15  µM Xn for 24  h. Virus 
was detected by virus titration. As shown in Figure  9A, 
Xn reduced the PRRSV titre in a dose-dependent manner 
in PAMs, which is consistent with the results in Marc-145 
cells. Then, we sought to identify the correlation between 
Xn and the Nrf2–HMOX1 axis in PAMs. PAMs were 
treated with 10  µM Xn for different times over 24  h, fol-
lowed by qRT-PCR for HMOX1 mRNA. Similar to in 
Marc-145 cells, HMOX1 mRNA was also induced by Xn in 
PAMs (Figure 9B). We also used different concentrations of 
CoPP to treat PAMs for 6 h, then washed them 3 times and 
infected with PRRSV (MOI 0.01). At 48 hpi, the levels of 
viral N-protein and HMOX1 in the cell lysates were exam-
ined by Western blotting. As expected, stimulating the 
expression of endogenous HMOX1 in PAMs significantly 
inhibited PRRSV replication in a dose-dependent manner 
(Figure 9C). Similarly, Xn induced HMOX1 and then inhib-
ited PRRSV in a dose-manner in PAMs (Figure 9D).
To further explore the role of Nrf2 in this process, 
PAMs were treated with Xn (5, 10, and 15  µM) and 
showed a dose-dependent increase in Nrf2 and HMOX1 
(Figure  9E). We next treated PAMs with 15  µM Xn for 
1 h and then infected them with PRRSV (MOI 0.01) for 
1 h. After washing the cells with PBS, culture medium 
containing Xn was added back. At 24 hpi, the cells 
were harvested for Western blotting. As shown in Fig-
ure  9F, PRRSV infection suppressed Nrf2 and HMOX1 
expression, but Xn treatment resulted in increased 
Nrf2 and HMOX1 expression and inhibition of PRRSV 
Figure 8 Xanthohumol suppresses oxidative stress induced by PRRSV in Marc‑145 cells. A ROS generation in Marc-145 cells was determined 
using dichlorofluorescein (DCF), and images were acquired using an inverted fluorescence microscope (Nikon). ImageJ was used to quantify the 
intensity of the green fluorescence in the pictures. B–D Effects of Xn on MDA, SOD and GSH levels in PRRSV-infected Marc-145 cells. All results are 
means ± standard deviations from three independent experiments performed in triplicate. ***P < 0.001; **P < 0.01; *P < 0.05 compared with the 
PRRSV-infected cells
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proliferation. Furthermore, Nrf2 expression knock-down 
also increased PRRSV replication in PAMs, and Xn had 
no inhibitory effect on PRRSV infection in PAMs trans-
fected with the siRNA targeting Nrf2 (Figures 9G and H). 
These data support that the restrictive features of Xn on 
PRRSV replication depend on the Nrf2–HMOX1 axis.
Given that Xn could alleviate PRRSV-stimulated oxida-
tive stress in Marc-145 cells, we also tested whether this 
effect occurred in PAMs. PAMs pre-treated with 12 µM 
 H2O2 for 3 h then incubated with 5 µM Xn produced less 
ROS than untreated cells. FACS analysis also showed 
that in PAMs, PRRSV infection resulted in increased 
ROS levels and that Xn treatment reduced ROS levels 
(Figure 10A); the raw flow cytometry data are shown in 
Additional file 2. The reduction in SOD and GSH levels 
as a result of PRRSV infection was alleviated by Xn (Fig-
ures  10B  and C). The elevated MDA levels in infected 
cells were reduced by Xn (Figure 10D).
Discussion
Natural products are a proven source of compounds 
for drug discovery, and the therapeutic use of plants 
has been known for millennia [28–30]. Natural com-
pounds and compositions have also been a rich source 
for drugs against many viruses. Ouabain extracted from 
the seeds of Strophanthus gratus, bufalin isolated from 
the venom of the Bufo toad, and valinomycin extracted 
from Streptomyces fulvissimus can inhibit PRRSV repli-
cation at micromolar concentrations in Marc-145 cells 
[31]. Sodium tanshinone IIA sulfonate extracted from 
Salvia miltiorrhiza inactivates PRRSV directly, thereby 
inhibiting replication in vitro [16]. Glycyrrhizin extracted 
from  liquorice root  inhibits penetration of PRRSV but 
has little effect on viral adsorption or release in Marc-145 
cells [32]. The mechanisms involved in these activities 
are not deeply understood. In this study, we screened a 
library of 386 natural products for anti-PRRSV activity. 
Xanthohumol significantly inhibited PRRSV prolifera-
tion in Marc-145 cells and PAMs and weakened PRRSV-
induced oxidative stress by activating the Nrf2–HMOX1 
pathway. It has promising therapeutic potential against 
PRRSV infection.
Xn is a prenylated flavonoid from the hop plant 
Humulus lupulus L [33]. Xn has anti-proliferative activ-
ity on breast, colon, and ovarian cancer cell lines [34]. 
Additionally, Xn has an anti-inflammatory effect on 
LPS-induced acute lung injury in mice [27], carbon tet-
rachloride-induced acute liver injury [35], and ischae-
mia reperfusion-induced liver injury [36]. Furthermore, 
Xn prevents cholesterol accumulation via CETP inhibi-
tion, leading to apoE upregulation in mice [37]. These 
research results demonstrate that Xn has a wide range 
of biological activities. We performed a transcriptome 
analysis of Xn-treated Marc-145 cells to initiate investi-
gation into the mechanism of Xn inhibition of PRRSV. 
We found an enrichment of pathways associated with the 
Nrf2 antioxidant stress response; among them, HMOX1 
was the most highly stimulated by Xn treatment. Haem 
oxygenase catabolizes haem and has three isoforms; 
HMOX1 is a rate-limiting enzyme in haem catabolism, 
leading to the generation of bilirubin, free iron, and 
carbon monoxide. HMOX1 is a stress response protein 
Figure 10 Xanthohumol suppresses oxidative stress induced by PRRSV in PAMs. A ROS generation in PAMs was determined using flow 
cytometry. The frequency of the cells that tested FITC positive among the total cells is shown in the lower right corner of the image. The histogram 
was used to quantify the number of FITC-positive cells in two independent trials. B–D Effects of 10 µM Xn on the levels of SOD, MDA, and GSH in 
PAMs infected with PRRSV or treated with  H2O2. All results are means ± standard deviations from three independent experiments performed in 
triplicate. ###P < 0.001; ##P < 0.01; #P < 0.05 vs  H2O2-treated group. ***P < 0.001; **P < 0.01; *P < 0.05 vs PRRSV-infected cells
(See figure on next page.)
(See figure on previous page.)
Figure 9 Xanthohumol upregulates the Nrf2–HMOX1 antioxidative axis to inhibit PRRSV proliferation in PAMs. A PAMs were pre-treated 
with DMSO or concentrations of Xn for 1 h and then infected with PRRSV (0.10 MOI) for 1 h at 37 °C. Cells were washed and incubated in fresh 
medium containing DMSO or Xn. At 24 hpi, cells were harvested for the viral titre. B PAMs were treated with 10 µM Xn for different times over 24 h, 
followed by qRT-PCR for HMOX1 mRNA. ***P < 0.001; **P < 0.01; *P < 0.05 vs DMSO-treated cells. C PAMs treated with CoPP (an inducer of HMOX1) 
for 6 h before PRRSV infection were examined for N-protein and endogenous HMOX1 by Western blotting. D PAMs were treated with an increasing 
multiplicity of Xn (0–10 µM) or DMSO for 1 h and then infected with PRRSV (MOI 0.01) for 1 h. After washing three times with PBS, culture medium 
containing Xn (0–10 µM) or DMSO was added back to the wells. At 24 hpi, the levels of HMOX1 and PRRSV N-protein were detected by Western 
blotting. E PAMs were treated with different doses of Xn for 24 h, and Nrf2 and HMOX1 were detected by Western blotting. F PAMs were treated 
with 15 µM Xn or DMSO for 1 h and then infected with PRRSV (MOI 0.01) for 1 h. After washing three times with PBS, culture medium containing 
15 µM Xn or DMSO was added back to wells. At 24 hpi, the levels of Nrf2, HMOX1 and PRRSV N-protein were detected by Western blotting. G, H 
PAMs were transfected with 50 pmol of siRNA targeting Nrf2. After 48 h, they were treated with 10 µM Xn or DMSO for 1 h and then infected with 
PRRSV (0.01 MOI). After 36 hpi, the mRNA levels of Nrf2 and PRRSV ORF7 were detected by qRT-PCR (G). Meanwhile, the levels of Nrf2, HMOX1 and 
PRRSV N-protein were detected by Western blotting (H). ***P < 0.001; **P < 0.01; *P < 0.05 compared with the control group
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that can be induced by various oxidative agents through 
Nrf2-mediated transcriptional activation of AREs [38]. 
It can maintain redox homeostasis, cooperating with 
other antioxidant enzymes. HMOX1 has also been 
shown to have significant antiviral effects [39–41]. We 
found that Xn could induce the expression of HMOX1 in 
Marc-145 cells and PAMs in a dose-dependent manner. 
Overexpressed or induced HMOX1 attenuated PRRSV 
replication in Marc-145 and PAM cells. Nuclear factor-
erythroid 2-related factor 2 (Nrf2) is an essential factor in 
the cell’s defence system, primarily regulating the expres-
sion of many genes involved in the oxidant response, 
such as HMOX1, NQO1, GCLC, and GCLM [42]. Tran-
scriptional activation of these enzymes is through mainly 
binding of Nrf2 to antioxidant response elements (AREs) 
on their 5′ promoter [43, 44]. The protective role of the 
Nrf2-ARE pathway has been examined in experimental 
models of various inflammatory and oxidative stress-
induced respiratory diseases. For example, Nrf2 via the 
Nrf2-mediated signalling pathway limits oxidative stress 
and weakens the severity of allergic airway inflamma-
tion caused by asthma [45]. The importance of the Nrf2 
pathway in viral pathogenesis was demonstrated in a 
study involving Nrf2 knockout mice. In that study, mice 
challenged with respiratory syncytial virus or influenza 
virus had elevated levels of viral replication and increased 
inflammatory responses and injury in their lungs [46]. 
Activation of the antioxidant pathways regulated by 
Nrf2 supports the regulation of antiviral and apoptotic 
responses by maintaining redox homeostasis in dengue 
virus-infected dendritic cells [47]. In this study, we found 
that Nrf2 had antiviral activity against PRRSV infec-
tion in Marc-145 cells and PAMs and that Xn directly 
targeted Nrf2 and stimulated the antioxidant pathways 
regulated by Nrf2. These results indicated that the Nrf2 
antioxidant pathway plays a role in the anti-PRRSV activ-
ity of Xn. Nrf2 is a latent transcription factor present in 
an inactive form in the cytoplasm of cells as a complex 
with inhibitory proteins such as Keap1 (Kelch-like-asso-
ciated protein1). Upon treatment with exogenous fac-
tors or induction of oxidative stress, Nrf2 is activated via 
the disruption of this complex, allowing the subsequent 
translocation of active Nrf2 to the nucleus, where it binds 
to ARE sequences to activate transcription of relevant 
inducible genes [48]. This mechanism is a very important 
aspect of Nrf2 biology and the cellular response to oxi-
dative stress. It should be determined whether transloca-
tion of Nrf2 from the cytoplasm to the nucleus of cells 
occurs upon PRRSV infection, Xn treatment or both.
Figure 11 Scheme summarizing the inhibitory effect of xanthohumol on PRRSV proliferation via activation of the Nrf2–HMOX1 axis. 
Xanthohumol, a prenylated flavonoid found in hops, inhibits PRRSV adsorption onto and internalization into cells. Xn treatment also stimulates Nrf2, 
which causes an increase in the levels of the antioxidant enzymes HMOX1, GCLC, GCLM, and NQO1 and a suppression of oxidative stress, resulting 
in a decrease in virus proliferation
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ROS generation is common in virus-infected cells. 
Cellular oxidative stress is significantly increased in 
dengue virus-infected dendritic cells [47]. Influenza 
virus infection increases reactive peroxynitrite forma-
tion and causes oxidative stress in lungs [49, 50], and 
PRRSV infection induces oxidative stress via ROS pro-
duction in Marc-145 cells [51, 52]. The upregulation of 
ROS is related to mitochondrial dysfunction [52]. PRRSV 
downregulates the expression of superoxide dismutase, 
reduces that of glutathione, and increases the production 
of ROS and malondialdehyde in Marc-145 cells, PAMs, 
and the lung tissues of infected pigs. We found that Xn 
treatment effectively decreased PRRSV-induced oxida-
tive stress. The Nrf2-mediated antioxidant response 
maintains an appropriate redox status and thus inhibits 
PRRSV-induced ROS damage.
The PRRSV life cycle can be divided into 4 basic stages: 
attachment, entry, replication and release [53, 54]. Our 
results showed that xanthohumol significantly inhib-
ited PRRSV adsorption and entry in Marc-145 cells and 
PAMs. Numerous host cell-dependent factors can affect 
and control PRRSV attachment and uptake by (i) the 
level of a specific virus receptor, such as CD163; (ii) host-
cell derived innate immune defence molecules aimed at 
binding and neutralizing the infectious virions; and (iii) 
antiviral mediators limiting viral replication [55]. There-
fore, modification of any or several of these factors by 
Xn treatment could affect susceptibility to PRRSV infec-
tion. Here, our data demonstrated that siRNA-medi-
ated knock-down of Nrf2 in MARC-145 cells increased 
PRRSV replication in these cells (Additional file  2). In 
addition, PRRSV infection induced oxidative stress. This 
result indicates that this virus-induced oxidative stress 
is beneficial for viral replication or that Nrf2 is involved 
in some way in the cellular innate antiviral response. 
In addition, we also noted that Xn downregulated the 
RNA expression of CD163, a key receptor of PRRSV [56] 
(Additional file 3). Nrf2 exists in most organs and affects 
the expression of nearly 500 proteins that act as redox 
balancing factors, detoxifying enzymes, stress response 
proteins and metabolic enzymes [57]. The changes in the 
cellular innate antiviral response, such as expression of 
RIG-I, IFN-β, and ISGs, and the receptor of PRRSV after 
treatment with Xn should be explored in the future.
In conclusion, (Figure  11), xanthohumol, a natural 
product derived from hops, effectively attenuated PRRSV 
proliferation and suppressed oxidative stress induced by 
PRRSV. These activities of Xn occurred largely via the 
activation of the Nrf2–HMOX1 pathway. This finding 
offers new and promising therapeutic possibilities for 
combating infections caused by PRRSV.
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incubated with PRRSV(1 MOI) for 1 h at 4 °C, washed, and incubated 
for another 1 h at 37 °C. The mRNA levels of PRRSV ORF7 and Nrf2 were 
detected by qRT-PCR. **P < 0.01; *P < 0.05 vs siNC group. 
Additional file 3. Xn treatment downregulated the CD163 mRNA 
levels in Marc‑145 cells. (A) Heat map of expressed genes modulated by 
10 µM Xn or DMSO treatment in Marc-145 cells. Red and blue correspond 
to relative up- and downregulation, respectively. (B) Marc-145 cells were 
treated with 10 µM Xn for 4, 8, 12 and 18 h, followed by qRT-PCR for 
CD163 mRNA levels. **P < 0.01; *P < 0.05 vs DMSO-treated cells.
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